RT Journal Article
SR Electronic
T1 A Large-Scale Observational Study on the Temporal Trends and Risk Factors of Opioid Overdose: Real-World Evidence for Better Opioids
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.08.20208678
DO 10.1101/2020.10.08.20208678
A1 Deng, Jianyuan
A1 Hou, Wei
A1 Dong, Xinyu
A1 Hajagos, Janos
A1 Saltz, Mary
A1 Saltz, Joel
A1 Wang, Fusheng
YR 2020
UL http://medrxiv.org/content/early/2020/11/12/2020.10.08.20208678.abstract
AB Background The United States is in the midst of an opioid overdose epidemic. We evaluated the temporal trends and risk factors of inpatient opioid overdose. Based on the opioid overdose patterns, we further examined the innate properties underlying less overdose events.Methods We conducted a retrospective cross-sectional study based a large-scale inpatient electronic health records database, Cerner Health Facts®. We included patients admitted between January 1, 2009 and December 31, 2017. Opioid overdose prevalence by year, demographics and prescription opioid exposures.Results A total of 4,720,041 patients with 7,339,480 inpatient encounters were retrieved from Cerner Health Facts®. Among them, 30.2% patients were aged 65+, 57.0% female, 70.1% Caucasian, 42.3% single, 32.0% from South and 80.8% in urban area. From 2009 to 2017, annual opioid overdose prevalence per 1,000 patients significantly increased from 3.7 to 11.9 with an adjusted odds ratio (aOR): 1.16, 95% confidence interval (CI): [1.15-1.16]. Comparing to the major demographic counterparts above, being in 1) age group: 41-50 (overall aOR 1.36, 95% CI: [1.31-1.40]) or 51-64 (overall aOR 1.35, 95% CI: [1.32-1.39]), marital status: divorced (overall aOR 1.19, 95% CI: [1.15-1.23]), 3) census region: West (overall aOR 1.32, 95% CI: [1.28-1.36]), were significantly associated with higher odds of opioid overdose. Prescription opioid exposures were also associated with increased odds of opioid overdose, such as meperidine (overall aOR 1.09, 95% CI: [1.06-1.13]) and tramadol (overall aOR 2.20. 95% CI: [2.14-2.27]). Examination on the relationships between opioid agonists’ properties and their association strengths, aORs, in opioid overdose showed that lower aORs values were significantly associated with 1) high molecular weight, 2) negative interaction with multi-drug resistance protein 1 (MDR1) or positive interaction with cytochrome P450 3A4 (CYP3A4) and 3) negative interaction with delta opioid receptor (DOR) or kappa opioid receptor (KOR).Conclusions The significant increasing trends of opioid overdose at the inpatient care setting from 2009 to 2017 indicated an ongoing need of efforts to combat the opioid overdose epidemic in the US. Risk factors associated with opioid overdose included patient demographics and prescription opioid exposures. Different prescription opioids were associated with opioid overdose to different extents, indicating a necessity to better differentiate them during prescribing practice. Moreover, there are physicochemical, pharmacokinetic and pharmacodynamic properties underlying less overdose events, which can be utilized to develop better opioids.Key PointsThere were significant increasing trends of opioid overdose at the US inpatient care setting from 2009 to 2017, showing an ongoing need for opioid overdose prevention.Different prescription opioids were associated with opioid overdose to different extents, indicating a necessity to differentiate prescription opioids during prescribing.The optimal properties underlying less overdose events mined from the large-scale, real-world electronic health records hold high potential to guide the development of better opioids with reduced overdose effects.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded partially by the Stony Brook University OVPR Seed Grant 1158484-63845-6.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Health Facts is a de-identified database. The use of the Health Facts data for research purposes is approved by Cerner and Stony Brook Medicine.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used for analysis is from Cerner Health Facts. https://www.cerner.com/